Citations 3
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Adekola, Kehinde , Anderson, Larry D. , Costello, Caitlin , Elsedawy, Noura, Faiman, Matthew , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Sborov, Douglas W. , Shain, Kenneth H. , Weber, Donna, Berardi, Ryan A., Kumar, Shaji , Holmberg, Leona , Anderson, Larry D , Callander, Natalie S. , Baljević, Muhamed , Campagnaro, Erica , Castillo, Jorge J. , Devarakonda, Srinivas , Garfall, Alfred L. , Kang, Yubin , Martin, Thomas G. , Stockerl‐Goldstein, Keith , Kumar, Rashmi
Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 8-19
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry D. , Castillo, Jorge J. , Chandler, Jason C., Costello, Caitlin , Efebera, Yvonne A. , Faiman, Matthew , Garfall, Alfred L. , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Shain, Kenneth H. , Sborov, Douglas W. , Stockerl‐Goldstein, Keith , Weber, Donna, Keller, Jennifer , Holmberg, Leona , Castillo, Jorge J , Anderson, Larry D , Garfall, Alfred L , Callander, Natalie S. , Baljević, Muhamed , Campagnaro, Erica , Kang, Yubin , Martin, Thomas G. , Kumar, Rashmi , Stockerl-Goldstein, Keith
Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1685-1717
Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Kumar, Shaji , Hillengaß, Jens , Liedtke, Michaela , Campagnaro, Erica , Chandler, Jason C., Cornell, Robert F. , Costello, Caitlin , Efebera, Yvonne A. , Faiman, Matthew , Garfall, Alfred L. , Godby, Kelly, Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Malek, Ehsan , Omel, James, Sborov, Douglas W. , Stockerl‐Goldstein, Keith , Tan, Carlyn , Weber, Donna, Johnson-Chilla, Alyse, Keller, Jennifer , Holmberg, Leona , Callander, Natalie S. , Baljević, Muhamed , Castillo, Jorge J. , Kang, Yubin , Landgren, Ola , Martin, Thomas G. , Raje, Noopur , Singhal, Seema , Kumar, Rashmi , Garfall, Alfred L , Campagnaro, Erica L , Stockerl-Goldstein, Keith
Journal of the National Comprehensive Cancer Network | October 7, 2019 | Volume: 17 | Issue: 10 | Pages: 1154-1165
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.